Aclaris Therapeutis (ACRS) PT Lowered to $34 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Aclaris Therapeutics (ACRS) Prices 8.6645M Share Common Offering at $10.75/Sh
October 18, 2018 5:45 AM EDTAclaris Therapeutics, Inc. (NASDAQ: ACRS) today announced the pricing of its underwritten public offering of 8,645,000 shares of its common stock at a price to the public of $10.75 per share. In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to... More
Aclaris Therapeutics (ACRS) Announces Proposed Common Share Offering
October 17, 2018 4:01 PM EDTAclaris Therapeutics, Inc. (Nasdaq: ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet patient needs in aesthetic and medical dermatology and immunology, today announced that it intends to offer and sell, subject to market... More
